Fludarabine
B Acute Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculePhase 2/3Active
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the B Acute Lymphoblastic Leukemia/Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
cd180 cart Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | CC |
sup19 car-t Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | CC |
ETOPOSIDE Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | CC |
Baffr Car-T Guangzhou Bio-gene Technology Co., Ltd | Early Phase 1 | C |
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →